PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7549453

Adrenalectomy does not prevent the ability of 8-OH-DPAT to decrease the ejaculatory threshold in male rats.

J Vega-Matuszczyk·S Ahlenius·P Eneroth·K Larsson
View original source ↗Export metadata ↓

Abstract

The present experiments demonstrate that 8-OH-DPAT (0.25 mg/kg SC, - 15 min) produced a decrease in the ejaculatory threshold to the same extent in adrenalectomized male rats as in sham operated controls. Both groups of animals displayed a marked and statistically significant decrease in number of mounts and penile intromissions preceding ejaculation and in the ejaculation latency, as a result of treatment with 8-OH-DPAT. Adrenalectomy per se did not affect any aspect of the male rat's sexual behavior (latency to first intromission, number of mounts or penile intromissions, ejaculation latency or the postejaculatory interval). The surgical removal of the adrenals was verified by measurements of plasma corticosterone levels. It is concluded that well documented effects of 8-OH-DPAT on adrenal secretions do not contribute to its ability to decrease the ejaculatory threshold in male rats.

Explore related subjects

8-Hydroxy-2-(di-n-propylamino)tetralinAdrenal GlandsAdrenalectomyAnimalsCorticosteroneEjaculationMaleRatsRats, WistarSexual Behavior, AnimalSodium ChlorideJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Vega-Matuszczyk, S Ahlenius, P Eneroth, K Larsson. 1995. Adrenalectomy does not prevent the ability of 8-OH-DPAT to decrease the ejaculatory threshold in male rats.. https://doi.org/10.1016/0924-977x(95)00008-d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Serotonin reduces synaptic excitation in the superficial medial entorhinal cortex of the rat via a presynaptic mechanism.

1. The superficial layers II and III of the entorhinal cortex, which form the main cortical input to the hippocampus, receive a large serotonergic projection from the raphe nuclei and express 5-HT receptors at high density. Here, we studied the effects of serotonin on the intrinsic properties and excitatory synaptic transmission of the superficial medial entorhinal cortex. 2. Intracellular and patch clamp recordings revealed that serotonin hyperpolarized only one-third of the cells, approximately, through a potassium conductance via a GTP-dependent process. 3. Serotonin depressed mixed as well as isolated alpha-amino-3-hydroxy-5-methyl-4-isoxazole- propionic acid receptor (AMPAR)- and N-methyl-D-aspartic acid receptor (NMDAR)-mediated excitatory postsynaptic potentials/currents (EPSPs/EPSCsapproximately 40 % reduction with 1 microM serotonin). 4. The effect of serotonin on EPSPs/EPSCs was similar in whole-cell versus intracellular recordings; it did not require intracellular GTP and was not visible in glutamate applications to excised patches. Miniature EPSCs recorded in the presence of tetrodotoxin and bicuculline were reduced in frequency, but not altered in amplitude. 5. The effects of serotonin on intrinsic properties and EPSPs were partially mimicked by 5-HT1A receptor agonists (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT) and 5-carboxamido-tryptamine maleate (5-CT), and reduced by 5-HT1A receptor antagonists S-(-)-5-fluoro-8-hydroxy-DPAT hydrochloride (S-UH-301), 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide (NAN-190) and spiperone. 6. We conclude that serotonin potently suppresses excitatory synaptic transmission via 5-HT1A receptors in layers II and III of the medial entorhinal cortex by a presynaptic mechanism.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1998

Effect of chronic amitriptyline administration on serotonergic receptors in rats with methylazoxymethanol-induced microencephaly.

Methylazoxymethanol (MAM)-induced cortical hypoplasia resulted in a 20% decrease in the Bmax of 5-HT2A receptors in the frontal cortex with no change in the Bmax of 5-HT1A receptors. Chronic treatment with amitriptyline did not further decrease the Bmax of 5-HT2A receptors in the MAM-lesioned cortex, suggesting that the persistent down-regulation of cortical 5-HT2A receptors in MAM-lesioned rats was induced by serotonergic hyperinnervation.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1998

Brain 5-HT1A receptor autoradiography and hypothermic responses in rats bred for differences in 8-OH-DPAT sensitivity.

Three rat lines were selectively bred for high (HDS), random (RDS), or low (LDS) hypothermic responses to the specific 5-HT1A receptor agonist 8-OH-DPAT. Forty-five minutes after 8-OH-DPAT administration (0.5 mg/kg), body temperatures dropped 3-5 degrees C in HDS rats, yet this dose produced only about 1.2 degrees C and 0.7 degree C drops in RDS and LDS rats, respectively. To investigate the relationship of body temperature of 5-HT1A receptor binding sites, autoradiographic analyses of [3H]8-OH-DPAT binding to 5-HT1A receptors in brains of these rats were conducted. Significant differences in binding were found in specific limbic cortical projection sites, with the HDS line having the greatest density of sites. Body temperature responses correlated significantly with [3H]8-OH-DPAT receptor binding in only a few areas of frontal cortex. Binding in many other brain regions, including the anterior and posterior hypothalami (regions long associated with body temperature regulation) and the raphe showed no significant differences among the lines. [3H]Ketanserin binding to cortical 5-HT2 receptors did not differ among the lines, except in the cingulate and superficial frontal cortices where HDS exhibited higher binding. These data suggest that differences in 5-HT1A receptor number may contribute to the exaggerated hypothermic response to 8-OH-DPAT in HDS rats. These studies also suggest that genetic regulation of receptor density may be brain region specific which should encourage future studies of the mechanisms of 5-HT1A receptor activity in brain and the action of drugs affecting this receptor.

8-Hydroxy-2-(di-n-propylamino)tetralin↗